TWSTTWSTHealthcare · Biotechnology

TWST Stock Forecast: Twist Bioscience Corp. Price Predictions for 2026-2027

Last close, 17 Nov 2026
$112
+6.63% on the day

The 13 Wall Street analysts covering Twist Bioscience Corp. hold a median 12-month price target of $136 — +21.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 16 Nov 2026 — in the upper half.

Market cap
$7.0B
Ticker Nerd rank
62/ 100
Median analyst target
$136
Analysts covering
13
Revenue$118.4M+23.2% y/y
Operating income−$36.3M
Net income−$35.1M
Free cash flow−$8.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−15.2%
1M
−15.6%
YTD
+253.1%
1Y
+323.3%
From 52W high
−45.4%
From 52W low
+340.1%
$25
$205
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TWST stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Twist Bioscience Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 16 Nov 2026
62/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
88
Momentum
87
Quality
81
Value
56
Growth
55
Accruals
42
Volatility
24
Issuance
24
Size
18

Revisions (88): Analysts have, on balance, been raising their forecasts.

Issuance (24): The company has been issuing shares or taking on financing, diluting existing holders.

Size (18): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TWST stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TWST, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150$200Jan 26Apr 26Jul 26Oct 26TWSTHigh $175Median $136Low $45

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
9 Buy3 Hold1 Sell
Low $45Median $136High $175

The green dot is the last close — the median target sits +21.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
16 Nov 2026BarclaysMaintainsOverweight$215 → $130
13 Nov 2026BairdMaintainsOutperform$187 → $135
13 Nov 2026Canaccord GenuityMaintainsBuy$205 → $150
13 Nov 2026Leerink PartnersMaintainsOutperform$190 → $175
13 Nov 2026TD CowenMaintainsBuy$190 → $137
13 Oct 2026TD CowenMaintainsBuy$115 → $190
13 Oct 2026TD CowenMaintainsBuy—
12 Oct 2026Canaccord GenuityMaintainsBuy$120 → $205
12 Oct 2026Canaccord GenuityMaintainsBuy—
8 Oct 2026JefferiesInitiatesHold—
8 Oct 2026JefferiesInitiatesHold$150
7 Oct 2026BarclaysMaintainsOverweight$112 → $215
7 Oct 2026BarclaysMaintainsOverweight—
1 Oct 2026GuggenheimMaintainsBuy—
1 Oct 2026GuggenheimMaintainsBuy$107 → $212
29 Sept 2026Leerink PartnersMaintainsOutperform—
29 Sept 2026Leerink PartnersMaintainsOutperform$160 → $190
18 Sept 2026BWS FinancialMaintainsSell$45
18 Sept 2026BWS FinancialMaintainsSell—
17 Sept 2026Leerink PartnersMaintainsOutperform$120 → $160

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

TWST appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TWST vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 17 Nov 2026, Twist Bioscience Corp. returned +323.3% against +11.2% for the S&P 500, dividends included.

TWST vs S&P 500, last 12 monthsTotal return, rebased to 100
0200400600800Jan 26Apr 26Jul 26Oct 26TWSTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TWST analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Twist Bioscience Corp. (TWST) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−80.9×

Cheaper than 99% of US stocks

Price / sales
15.2×

Cheaper than 9% of US stocks

Price / book
7.7×

Cheaper than 11% of US stocks

EV / EBITDA
−59.4×

Cheaper than 96% of US stocks

Growth & margins
Revenue growth (YoY)
27.9%

Higher than 76% of US stocks

Earnings growth (YoY)
23.2%

Higher than 62% of US stocks

Gross margin
52.8%

Higher than 65% of US stocks

Operating margin
−28.8%

Higher than 20% of US stocks

Net margin
−28.3%

Higher than 13% of US stocks

Returns & dividend
Return on equity
−19.1%

Higher than 32% of US stocks

Return on assets
−9.4%

Higher than 27% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Twist Bioscience Corp. (TWST) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Twist Bioscience Corp. has a market value of $7.0B and an enterprise value of $6.4B.

  • Revenue in the twelve months to 30 June 2026: $431.8M. The latest quarter grew 27.9% year on year.

  • Net income over the same four quarters: −$136.7M, a −31.7% net margin.

  • Diluted earnings per share, trailing twelve months: −$2.22.

  • Free cash flow in the twelve months to 30 June 2026: −$93.2M.

  • Twist Bioscience Corp. spent $18K on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 62.7M.

  • Trailing P/E: −80.9×; forward P/E: 1607.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Twist Bioscience Corp. employs 979 people — $441K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Nov 2026

Data provided by Twelve Data

Peers

TWST vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TWSTTwist Bioscience Corp.$7.0B62
AXSMAxsome Therapeutics, Inc.$7.1B73
IMVTImmunovant, Inc.$6.7B58
KODKodiak Sciences, Inc.$6.6B59
ORKAOruka Therapeutics, Inc.$6.6B37
CYTKCytokinetics, Inc.$7.4B61
RYTMRhythm Pharmaceuticals, Inc.$7.4B84

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Twist Bioscience Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TWST news & analysis

Twist Bioscience: Long-Term 'Buy' On AI Discovery For Biotech

Seeking Alpha · 16 Nov 2026positive

A Seeking Alpha article presents a long-term bullish view of Twist Bioscience, arguing that AI drug discovery, repeat testing, lab data work, and personalized cancer testing could expand customer demand for the company’s services.

Why it matters — The article’s growth case centers on potential opportunities across drug discovery and diagnostics that may interest TWST watchers.

Twist Bioscience Q4 Earnings Call Highlights

MarketBeat · 12 Nov 2026positive

Twist Bioscience reported 28% revenue growth and positive adjusted EBITDA in its fiscal fourth quarter. Full-year sales increased 22%, supported by demand for DNA, proteins and data used in AI drug discovery.

Why it matters — The results highlight quarterly growth and demand across offerings relevant to TWST watchers.

Twist Bioscience: 3 Key Takeaways for Long-Term Investors

The Motley Fool · 12 Nov 2026positive

The Motley Fool highlighted three takeaways for long-term investors, including fourth-quarter revenue growth of 28% year over year to $126.6 million and fiscal 2026 AI drug discovery revenue of $59.1 million.

Why it matters — The figures provide TWST watchers with a snapshot of reported revenue growth and AI drug discovery revenue.

Twist Bioscience Corporation (TWST) Q4 2026 Earnings Call Transcript

Seeking Alpha · 12 Nov 2026neutral

Seeking Alpha published a transcript of Twist Bioscience Corporation’s Q4 2026 earnings call. The supplied excerpt contains only the headline and no details from the call.

Why it matters — TWST watchers can refer to the earnings-call transcript, but the provided text does not describe the company’s results or management’s comments.

Alger Mid Cap 40 ETF Q3 2026 Portfolio Review

Seeking Alpha · 12 Nov 2026positive

Twist Bioscience was among the top contributors to performance in the Alger Mid Cap 40 ETF’s Q3 2026 portfolio review. The excerpt does not provide further detail on Twist’s contribution.

Why it matters — The review identifies Twist as a positive contributor to the fund’s performance during the quarter.

FAQ

Frequently asked questions about TWST stock

What is the TWST stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Twist Bioscience Corp. have a median 12-month price target of $136, with estimates ranging from $45 to $175. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TWST stock a buy right now?

Of the 13 analysts covering Twist Bioscience Corp., 9 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Twist Bioscience Corp. 62 out of 100 across roughly 4,600 US stocks as at 16 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TWST?

As at 16 Nov 2026, Twist Bioscience Corp. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (88 of 100).

Will TWST stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +21.4% from the last close, and Ticker Nerd's factor model ranks Twist Bioscience Corp. 62 out of 100 as at 16 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TWST stock forecast for 2030?

No analyst covering Twist Bioscience Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TWST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $45 to $175 over the next 12 months.

How has TWST stock performed over the past year?

Twist Bioscience Corp. returned +323.3% over the 12 months to 17 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Twist Bioscience Corp. do?

Twist Bioscience Corporation is a synthetic biology company that develops and sells DNA-based products for research and commercial applications. Twist Bioscience Corporation’s portfolio includes synthetic genes, gene fragments, oligonucleotide pools, and antibody libraries used in therapeutic discovery, diagnostics, agriculture, industrial biotechnology, and academic research.

What is the latest news on TWST?

The most recent item we track (Seeking Alpha, 16 Nov 2026): "Twist Bioscience: Long-Term 'Buy' On AI Discovery For Biotech". A Seeking Alpha article presents a long-term bullish view of Twist Bioscience, arguing that AI drug discovery, repeat testing, lab data work, and personalized cancer testing could expand customer demand for the company’s services.

Company

About Twist Bioscience Corp.

Twist Bioscience Corporation is a synthetic biology company that develops and sells DNA-based products for research and commercial applications. Twist Bioscience Corporation’s portfolio includes synthetic genes, gene fragments, oligonucleotide pools, and antibody libraries used in therapeutic discovery, diagnostics, agriculture, industrial biotechnology, and academic research. The company also supports advanced workflows such as targeted next-generation sequencing, CRISPR gene editing, mutagenesis, and DNA data storage. Its proprietary semiconductor-based DNA synthesis platform is designed to produce high-quality synthetic DNA at scale, helping customers move from design to experimentation more efficiently. Twist Bioscience Corporation serves biotechnology, pharmaceutical, industrial, and academic customers across multiple regions, making it an important supplier in the life sciences tools and synthetic biology market.

CEO Dr. Emily Marine Leproust Ph.D. · 979 employees · United States · https://www.twistbioscience.com